3 unknown. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Unknown 3 |
| Phase 2 | 3 | Unknown 3 |
Follow ALK-Positive Anaplastic Large Cell Lymphoma: new trials by email Literature Review of ALK-Positive Anaplastic Large Cell Lymphoma trials Research Report on ALK-Positive Anaplastic Large Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL PD-1 Antibody, Lenalidomide - Non-GCB/ABC Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huiqiang Huang | 30 | 2021-03-31 | 2021-03-15 |
| Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL Camrelizumab, Apatinib - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huiqiang Huang | 33 | 2020-07-23 | 2021-03-15 |
| Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma Toripalimab, Rituximab, R-CHOP Protocol - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huiqiang Huang | 140 | 2020-04-24 | 2022-04-14 |
Pyloric Stenosis, Hypertrophic (3) · Lymphoma, Large B-Cell, Diffuse (2) · Recurrence (2)
Digestive System Diseases (3) · Gastric Outlet Obstruction (3) · Gastrointestinal Diseases (3) · Pyloric Stenosis (3) · Stomach Diseases (3) · Disease Attributes (2) · Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoma (2) · Lymphoma, B-Cell (2) · Lymphoma, Non-Hodgkin (2) · Lymphoproliferative Disorders (2) · Neoplasms (2)
Lenalidomide (1) · R-CHOP protocol (1) · Rituximab (1) · apatinib (1) · camrelizumab (1) · spartalizumab (1) · tislelizumab (1) · toripalimab (1)
Huiqiang Huang (3)
China (3)